STL Index for: Trametinib
Casmo Prevention and Management of Four Common Cutaneous Toxicities Associated with Targeted Cancer Therapies: Papulopustular Eruption, Xerosis, Paronychia, and Hand-Foot Skin Reaction
Advances in cancer treatment have contributed to a reduction in mortality but survivors and healthcare providers should be aware of the potential adverse effects of these advanced treatments.
Update on Immunotherapeutics in the Management of Metastatic Melanoma
There are many new immunotherapeutics that have been approved or are in clinical and pre-clinical trials to expand our arsenal in the treatment of melanoma and other previously difficult to treat malignancies.
Skin Treatments Introduced in 2014
An overview and update of skin treatments introduced in 2014: Quick overview of drug name, indications and regulatory status. Clindamycin phosphate 1.2% + benzoyl peroxide 3.75% gel (Onexton™), Doxycycline hyclate tablets (Acticlate™), Tretinoin gel microsphere 0.08% (Retin-A Micro®) and many other drugs are covered.
Update on Drugs and Drug News: March-April 2014
Update on Trametinib + Dabrafenib (Mekinist® + Tafinlar®), Tretinoin gel microsphere 0.08% (Retin-A Micro®), Fluocinonide cream 0.1%, Hydrogel wound dressing (Loutrex®), Scar treatment (Microcyn®)